GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Merus N.V.
Shares of Merus, a biotech company developing bispecific antibodies for cancer treatment, are extremely volatile. Their price reflects not revenue, but rather news about clinical trials and investor confidence in the potential of its unique scientific platform.
Share prices of companies in the market segment - Cancer women
Merus is a biotech company developing bispecific antibodies for cancer treatment. We classify it in the "Women's Cancer" sector. The chart below shows the overall performance of this biotech segment, not just MRUS stock.
Broad Market Index - GURU.Markets
Merus is a Dutch biotech company developing innovative bispecific antibodies for cancer treatment. As a leading player in oncology, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how investors view this complex yet promising area of biotech.
Change in the price of a company, segment, and market as a whole per day
MRUS - Daily change in the company's share price Merus N.V.
Change_Co for Merus N.V. (MRUS), a biotech company developing cancer therapies, reflects hypersensitivity to clinical results and partnerships. MRUS volatility is a measure of the extreme volatility inherent in innovative oncology. This metric is critical for formulaic modeling of risks and potential in the biotech sector.
Daily change in the price of a set of shares in a market segment - Cancer women
Merus N.V. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with MRUS's performance, which depends on the results of clinical trials of its bispecific antibodies, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Merus is a biopharmaceutical company developing innovative bispecific antibodies for cancer treatment. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating Merus stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Merus N.V.
Merus is a Dutch biotech company focused on women's health. Its US-listed shares bring the dynamism of the European biotech sector to the market. These international factors complicate the overall market volatility picture.
Annual dynamics of market capitalization of the market segment - Cancer women
Merus N.V. is a biotech company developing innovative bispecific antibodies for cancer treatment. Its platform enables the creation of drugs that can attack cancer cells in multiple ways. The chart below shows how the market perceives the potential of its unique technology in oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Merus is a biotech company whose future depends on the success of its innovative cancer treatments. Its stock price is completely disconnected from economic cycles. The chart reflects scientific events—news about clinical trials and regulatory decisions—rather than macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Merus N.V.
The dynamics of Merus, a biopharmaceutical company, are speculative. The monthly fluctuations on the chart reflect not revenue, but news about clinical trials of its bispecific antibodies for cancer treatment, the success of which determines the company's entire future value.
Monthly dynamics of market capitalization of the market segment - Cancer women
This chart reflects the dynamics of the biotech sector. For Merus, with its innovative bispecific antibody platform, it's the backdrop. Its movements demonstrate how positive data from early clinical trials can create high expectations for the entire niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Merus N.V. is a clinical-stage biopharmaceutical company developing innovative bispecific and trispecific antibodies for the treatment of cancer. The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to illustrate how scientific data and partnerships have driven its stock price movement completely independent of overall sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Merus N.V.
Merus N.V. is a biotech company developing innovative cancer treatments. Its weekly stock price is highly volatile, driven by clinical trial data releases and partnerships with major pharmaceutical companies. The chart reflects the high hopes and risks in oncology.
Weekly dynamics of market capitalization of the market segment - Cancer women
Merus N.V. is part of the volatile biotech sector, where investor sentiment can shift across the entire industry. A breakthrough in one company can spur interest in the entire segment. The chart shows how Merus compares to the overall biotech industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Merus N.V. is a biotech company developing cancer drugs. Its shares follow the rhythm of clinical trial news. This chart is a great way to see how its weekly fluctuations are detached from overall market trends. Is it ignoring macroeconomic noise and following its own trajectory?
Market capitalization of the company, segment and market as a whole
MRUS - Market capitalization of the company Merus N.V.
The Merus N.V. chart is a visualization of the hopes in the field of immuno-oncology. Its market capitalization reflects investors' faith in the platform for creating bispecific antibodies capable of fighting cancer. The chart's dynamics are not sales estimates, but expectations for clinical trial results.
MRUS - Share of the company's market capitalization Merus N.V. within the market segment - Cancer women
Merus N.V. is a biotech company specializing in the development of innovative bispecific antibodies for cancer treatment. Its market cap in the oncology sector reflects the potential of its Biclonics platform. The chart below reflects investors' bets that its unique approach will lead to therapeutic breakthroughs and significant growth.
Market capitalization of the market segment - Cancer women
Merus is developing innovative bispecific antibodies for cancer treatment. How big is the overall oncology innovation arena? The chart below shows the total market capitalization of this biotech sector. Its growth reflects the enormous investment and hopes associated with finding new, more effective ways to fight cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Merus N.V. chart is a visualization of the company's bet on next-generation cancer treatments. This biotech's market cap is based on the potential of its bispecific antibody platform. The chart's dynamics are not a reflection of current revenue, but rather a barometer of investor confidence in the success of clinical trials and future breakthroughs.
Book value capitalization of the company, segment and market as a whole
MRUS - Book value capitalization of the company Merus N.V.
For Merus, a biotech company developing cancer treatments, book value is its tangible assets: laboratories, antibody production equipment, and financial reserves. The chart below shows how the company built its physical foundation to support cutting-edge scientific research.
MRUS - Share of the company's book capitalization Merus N.V. within the market segment - Cancer women
Merus N.V. is fighting cancer, and its tangible assets include cutting-edge biotechnology laboratories and development centers. These facilities, equipped with unique equipment, are where innovative bispecific antibodies are created. The chart below shows the share of this science-intensive research infrastructure the company controls in its niche.
Market segment balance sheet capitalization - Cancer women
Merus is a biotech company whose value lies in its antibody research platform. It's a classic example of a capital-light business. The chart below illustrates the capital intensity of the pharmaceutical sector, highlighting its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Merus develops innovative bispecific antibodies for cancer treatment. Its balance sheet, consisting of laboratories and capital, is small relative to the market. This stake in BCap_All represents a material resource the company is dedicating to the development of therapies that could change the paradigm of cancer treatment.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Merus N.V.
Merus is a biotech company with a unique platform for creating antibodies. Its balance sheet is minimal. Its market capitalization is a bet on a scientific breakthrough. The P/B ratio is off the charts because investors are buying not assets, but intellectual property and the hope of creating a new class of cancer drugs.
Market to book capitalization ratio in a market segment - Cancer women
Merus N.V. is a biotech company specializing in the development of bispecific antibodies for cancer treatment. Its market capitalization is based almost entirely on expectations for its scientific platform. This metric illustrates the significant premium investors pay for innovative potential in oncology.
Market to book capitalization ratio for the market as a whole
Merus N.V. is a biotechnology company specializing in the development of innovative bispecific antibodies for cancer treatment. Compared to average market valuations shown in this chart, its high premium reflects the potential of its scientific platform and investors' belief that its drugs will become new standards in oncology.
Debts of the company, segment and market as a whole
MRUS - Company debts Merus N.V.
Merus N.V., a biopharmaceutical company developing bispecific antibodies for cancer treatment, is raising capital to finance its innovative platform. The debt instruments are helping the company conduct numerous preclinical and clinical trials, which are critical to bringing new oncology drugs to market.
Market segment debts - Cancer women
Merus N.V. is a biotech company specializing in the development of innovative bispecific antibodies for cancer treatment. Financing in this field is critical for conducting expensive clinical trials. This chart shows whether Merus uses debt instruments in its financing strategy, which may indicate confidence in its developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Merus N.V.
Merus N.V. is a biotechnology company specializing in the development of innovative cancer treatments. Its activities are entirely focused on research and clinical trials. This chart shows its financial structure, which is likely based on equity rather than debt, which is typical for pre-commercial companies.
Market segment debt to market segment book capitalization - Cancer women
Merus N.V. is a biotechnology company specializing in the development of innovative bispecific antibodies for cancer treatment. This chart shows the overall debt burden in the oncology segment. It helps understand how the industry finances expensive clinical trials and how Merus's capital raising strategy compares to this.
Debt to book value of all companies in the market
Merus, an oncology biotech, requires significant capital for R&D. This chart shows the overall risk appetite across the market. It helps us understand how favorable the current macroeconomic environment is for funding breakthrough, yet long-term and risky, projects like Merus's.
P/E of the company, segment and market as a whole
P/E - Merus N.V.
Merus N.V. is a biotech company developing innovative bispecific antibodies for cancer treatment. This chart shows that the company's valuation is based on the scientific potential of its platform and the prospects for future clinical success. Investors are investing not in current profits, but in the potential to create breakthrough oncology drugs.
P/E of the market segment - Cancer women
The biotech sector, where Merus develops innovative cancer drugs, is valued based on future potential. This chart shows the average valuation for commercially successful biotechs. It provides context to understand that Merus's valuation is based on its scientific platform, not its current financial performance.
P/E of the market as a whole
Merus N.V. is a biotech company specializing in the development of bispecific antibodies for cancer treatment. Its valuation, like that of other companies at this stage, is entirely dependent on clinical trial data. General market sentiment, reflected in this chart, is completely irrelevant compared to news about the efficacy and safety of its experimental drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Merus N.V.
Merus N.V. is a biotechnology company specializing in the development of innovative bispecific antibodies for cancer treatment. For a clinical-stage company, this chart is an indicator of analysts' confidence in its scientific platform. It reflects expectations for the results of upcoming studies and the potential for future partnerships or drug approvals.
%20P%2FE%20Merus%20N.V.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Merus-N.V.&v=1772545610007 "Chart of the company's future (projected) P/E Merus N.V.")
Future (projected) P/E of the market segment - Cancer women
Merus N.V. is a Dutch biotech company developing innovative bispecific antibodies for cancer treatment. This indicator compares the company's profitability expectations with the oncology sector. It assesses investor confidence in its proprietary Biclonics platform and the potential of its drugs in clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-women&v=1772545610014 "Future (projected) P/E graph of the market segment - Cancer women")
Future (projected) P/E of the market as a whole
Merus N.V. is a biotech company developing innovative drugs (bispecific antibodies) for cancer treatment. This chart shows the overall market appetite for risk. Merus's success depends on scientific breakthroughs and clinical trial results. A positive environment helps attract capital but cannot replace fundamental scientific advances.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772545610020 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Merus N.V.
Merus N.V. is a biotechnology company specializing in the development of innovative bispecific antibodies for cancer treatment. This chart shows the financial trajectory of the company, which is at the forefront of oncology. Current results reflect significant investments in research and development aimed at creating a new generation of anti-cancer drugs.
Profit of companies in the market segment - Cancer women
Merus is a biotech company specializing in the development of innovative bispecific antibodies for cancer treatment. Its Biclonics platform enables the creation of drugs that attack tumors in multiple ways. This graph illustrates the total revenue in the oncology sector, demonstrating the commercial success of new cancer therapy approaches.
Overall market profit
Merus N.V. is a biotech company developing innovative cancer treatments using bispecific antibodies. Like other companies in clinical trials, Merus prioritizes scientific data over economic cycles. However, the overall positive market environment, driven by the growth in this chart, facilitates capital raising.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Merus N.V.
Merus develops innovative bispecific antibodies for cancer treatment that can attack tumor cells from multiple directions simultaneously. This is a cutting-edge field in oncology. The revenue projection presented here is a long-term model based on an assessment of the scientific and commercial potential of its unique technology platform.
%20profit%20of%20the%20company%20Merus%20N.V.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Merus-N.V.&v=1772545610049 "Graph of future (projected) profit of the company Merus N.V.")
Future (predicted) profit of companies in the market segment - Cancer women
Merus N.V. is a biotechnology company specializing in the development of innovative bispecific antibodies for cancer treatment. This chart reflects forecasts for the oncology segment of the biotech sector. Merus's platform enables the creation of "smart" drugs capable of simultaneously attacking cancer cells on multiple fronts, potentially representing a breakthrough in therapeutics.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-women&v=1772545610073 "Graph of future (predicted) profits of companies in a market segment - Cancer women")
Future (predicted) profit of the market as a whole
Merus is developing innovative bispecific antibodies for cancer treatment. Like many biotech companies, its short-term success depends more on clinical data than on economic performance. However, the overall market return forecast in this chart is important, as it determines investor risk appetite and the availability of capital to fund research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772545610095 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Merus N.V.
Merus N.V. is a biotechnology company specializing in the development of innovative bispecific antibodies for cancer treatment. The company's valuation, reflected by this metric, is based on expected future revenue from its Biclonics platform. The chart demonstrates investors' confidence in the scientific breakthrough and commercial potential of its developments.
P/S market segment - Cancer women
Merus N.V. is a biotech company specializing in the development of innovative bispecific antibodies for cancer treatment. The company's valuation is based on the potential of its Biclonics platform. This chart reflects the average valuation in biotech companies, helping investors understand how highly the market values Merus's scientific approach compared to other oncology companies.
P/S of the market as a whole
Merus is developing innovative bispecific antibodies for cancer treatment. This is a cutting-edge field in oncology. For a company in clinical development, revenue is minimal, and its valuation is based on the potential of its scientific platform. This graph of average market revenue estimates contrasts sharply with Merus's valuation, demonstrating investor confidence in a future breakthrough.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Merus N.V.
Merus N.V. is a biotech company developing innovative bispecific antibodies for cancer treatment. This chart reflects investor expectations for future revenue, which are entirely dependent on the success of clinical trials. It demonstrates the market's confidence in the potential of the Biclonics platform to create breakthrough oncology drugs.
%20P%2FS%20Merus%20N.V.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Merus-N.V.&v=1772545610114 "The graph of the company's future (projected) P/S Merus N.V.")
Future (projected) P/S of the market segment - Cancer women
Merus develops innovative bispecific antibodies for cancer treatment. This chart compares the company's future revenue expectations with those of the biotech sector. For a clinical-stage company, it reflects the market's assessment of the scientific potential of its platform and confidence in the success of future drugs.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20women&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-women&v=1772545610119 "Future (projected) P/S market segment graph - Cancer women")
Future (projected) P/S of the market as a whole
Merus N.V. is a biotechnology company specializing in the development of innovative bispecific antibodies for cancer treatment. This chart shows general expectations for future revenue, and Merus is an example of the source of these expectations. The company's breakthrough technologies in oncology could create new treatment standards and open multibillion-dollar markets, fulfilling these projections.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772545610140 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Merus N.V.
Merus is a clinical-stage biotechnology company developing innovative cancer treatments. Its revenue is typically generated not through sales, but through upfront and milestone payments from major pharmaceutical companies through collaboration and licensing agreements.
Sales of companies in the market segment - Cancer women
Merus N.V. is a biotechnology company specializing in the development of innovative bispecific antibodies for cancer treatment. Their platform enables the creation of drugs that attack cancer cells from multiple angles. This graph reflects the cumulative progress in oncology, where breakthrough approaches like Merus's have the potential to radically change the standard of treatment.
Overall market sales
Merus N.V. is a biotechnology company specializing in the development of innovative cancer treatments. Its operations rely on capital inflows into knowledge-intensive industries. Periods of revenue growth, reflected in the graph, typically coincide with investor willingness to invest in long-term, high-risk projects, which is critical to funding Merus's research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Merus N.V.
Merus N.V. is a clinical-stage biotechnology company developing innovative bispecific antibodies (Biclonics®) for the treatment of cancer. Its future sales forecast reflects analyst expectations regarding the success of its clinical programs and potential partnerships with major pharmaceutical companies. This is a bet on a breakthrough in immuno-oncology.
%20sales%20of%20the%20company%20Merus%20N.V.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Merus-N.V.&v=1772545610188 "Schedule of future (projected) sales of the company Merus N.V.")
Future (projected) sales of companies in the market segment - Cancer women
Merus N.V. is a biotechnology company developing innovative bispecific antibodies for cancer treatment. Their Biclonics platform enables the creation of drugs that simultaneously target multiple tumors. This chart shows forecasts for the oncology sector, providing context for assessing the potential of Merus's breakthrough technologies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-women&v=1772545610224 "Schedule of future (projected) sales of companies in the market segment - Cancer women")
Future (projected) sales of the market as a whole
Merus N.V., a biopharmaceutical company developing innovative cancer treatments, sees this chart as a marker of the overall investment climate. The optimistic economic forecasts reflected here are driving capital flows into the high-risk but promising biotech sector, which is essential for funding their research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772545610288 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Merus N.V.
Merus N.V. is a biotechnology company specializing in the development of innovative bispecific antibodies for the treatment of cancer. While in clinical trials, the company incurs significant R&D expenses. This chart reflects its financial position, demonstrating how effectively it manages capital to advance its drug candidates to commercialization.
Market segment marginality - Cancer women
Merus is a Dutch biotechnology company specializing in the development of innovative bispecific antibodies (Biclonics) for the treatment of oncology. This chart reflects its financial performance in the context of the industry. For a company in clinical development, profitability can vary greatly depending on partnerships and development stages.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Merus N.V.
Merus N.V. is a biopharmaceutical company developing innovative bispecific antibodies for cancer treatment. This chart reflects the growth of its scientific team. For a company at the clinical trial stage, increasing the number of scientists and researchers is a key indicator of progress in the development and testing of new promising drugs.
Share of the company's employees Merus N.V. within the market segment - Cancer women
Merus is developing innovative bispecific antibodies for cancer treatment. In this highly competitive field of biotech, scientific talent is the most valuable resource. This chart shows the percentage of leading scientists Merus attracts in its niche, a direct indicator of its research potential and ambition to create breakthrough drugs.
Number of employees in the market segment - Cancer women
Merus N.V. is a biotechnology company specializing in the development of innovative bispecific antibodies for cancer treatment. Its main resource is its team of scientists. This graph shows the growth of its intellectual capital. The increase in headcount directly reflects progress in clinical trials and the expansion of its oncology drug portfolio.
Number of employees in the market as a whole
Merus N.V. is a biotechnology company specializing in the development of innovative cancer treatments. Its growth is driven by scientific advances and clinical trial results. Unlike the general labor market dynamics reflected in this graph, hiring at Merus is an investment in the future of oncology, where every specialist can contribute to saving lives.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Merus N.V. (MRUS)
Merus N.V. is a biotech company developing innovative cancer treatments (bispecific antibodies). Its enormous market capitalization, despite its small staff, reflects investors' bet on scientific breakthroughs. This chart shows the astronomical value of each scientist, reflecting the value of their intellectual labor.
%20of%20the%20company%20Merus%20N.V.%20(MRUS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Merus-N.V.-MRUS&v=1772545610673 "Chart of market capitalization per employee (in thousands of dollars) of the company Merus N.V. (MRUS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer women
Merus N.V. is a biotech company specializing in the development of bispecific antibodies (Multiclonics) for cancer treatment. This chart shows the average capitalization per employee in the sector. Like other R&D companies, it demonstrates the market's confidence in their unique scientific platform and team of scientists per employee.
%20by%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-women&v=1772545610773 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer women")
Market capitalization per employee (in thousands of dollars) for the overall market
Merus is developing innovative bispecific antibodies for cancer treatment. Like many research-stage biotech companies, its value is determined by the potential of its scientific developments. This chart demonstrates the enormous value the market places on each scientist and employee, expecting them to achieve breakthroughs in oncology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772545610857 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Merus N.V. (MRUS)
Merus N.V. is a biotech company specializing in the development of innovative bispecific antibodies (Biclonics) for cancer treatment. It's an R&D platform. This chart reflects the effectiveness of their research. As with other biotech companies, it demonstrates the bet that a small team of scientists will create a breakthrough drug with enormous market potential.
%20Chart%20Merus%20N.V.%20(MRUS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Merus-N.V.-MRUS&v=1772545610962 "Company Profit Per Employee (in thousands of dollars) Chart Merus N.V. (MRUS)")
Profit per employee (in thousands of dollars) in the market segment - Cancer women
Merus N.V. is a clinical-stage biotech company developing "bispecific" antibodies for cancer treatment. This chart shows the benchmark for "Cancer" (Biotech). In this sector, the benchmark is likely *negative*. Companies burn billions on R&D. Profit per employee (scientist) is a goal for the distant future.
%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-women&v=1772545611037 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer women")
Profit per employee (in thousands of dollars) for the market as a whole
Merus (MRUS) is a Dutch biotech company specializing in the development of bispecific antibodies (Multiclonics®) for cancer treatment. Their technology enables them to attack multiple targets simultaneously. This graph, showing average profit per employee, is important for biotech. It allows us to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772545611065 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Merus N.V. (MRUS)
Merus N.V. is a biotech company specializing in the development of innovative cancer treatments (bispecific antibodies). At the clinical trial stage, this graph reflects potential rather than current sales. Revenue per employee is typically generated through partnerships and is an indicator of the pharma giants' faith in their technology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Merus-N.V.-MRUS&v=1772545611094 "Sales chart per company employee Merus N.V. (MRUS)")
Sales per employee in the market segment - Cancer women
Merus N.V. is a biotech company specializing in the development of bispecific antibodies (Biclonics) for cancer treatment. This is complex science. This chart shows the average revenue per employee in the segment. It is important for assessing how effectively Merus utilizes its scientific potential to create commercially successful drugs compared to other oncology biotechs.
Sales per employee for the market as a whole
Merus N.V. is a biotech company developing innovative bispecific antibodies for cancer treatment. It is a research-intensive business in the clinical development stage. This chart shows the revenue (from partnerships) generated per scientist and how the company is beginning to monetize its complex R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company Merus N.V. (MRUS)
Merus is a biotech company specializing in the development of bispecific antibodies (Biclonics) for cancer treatment. This is a cutting-edge but risky sector. The chart reflects the volume of downside bets from investors who doubt the company's clinical data, fear intense competition in immuno-oncology, or believe the path to approval will be too long.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Merus-N.V.-MRUS&v=1772545611369 "Short Shares Chart for the Company Merus N.V. (MRUS)")
Shares shorted by market segment - Cancer women
Merus N.V. is a biotech company developing innovative bispecific antibodies for cancer treatment. This is a high-risk industry. This indicator summarizes bets against the entire biotech sector. It reflects the overall skepticism of investors: they may fear not only Merus's failures but also funding or regulatory issues across the industry.
Shares shorted by the overall market
Merus (MRUS) is a clinical-stage biotech (oncology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives MRUS of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Merus N.V. (MRUS)
Merus is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart for Merus can soar above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks or a general aversion to risk in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Merus-N.V.-MRUS&v=1772545611463 "RSI 14 indicator chart for the company's stock Merus N.V. (MRUS)")
RSI 14 Market Segment - Cancer women
Merus (MRUS) is a biotech company specializing in the development of bispecific antibodies (Biclonics) for the treatment of cancer, including breast cancer. This chart tracks overall sentiment in the Oncology sector. It helps investors understand whether Merus's move is a reaction to its clinical data or whether the entire sector is overheated or oversold due to general biotech sentiment.
RSI 14 for the overall market
Merus N.V. is a biotech company developing innovative drugs (bispecific antibodies) for cancer treatment. This cutting-edge science requires massive funding. This graph, reflecting investors' risk appetite, is critical for the company. Market panic is closing the window for raising capital needed to continue expensive R&D.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MRUS (Merus N.V.)
Merus N.V. is a biotech company specializing in the development of bispecific antibodies (Biclonics) for the treatment of cancer, particularly breast cancer and head and neck tumors. This chart shows the average price target from analysts, reflecting their expectations for clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MRUS-Merus-N.V.&v=1772545611594 "A chart showing analyst consensus forecasts for the expected stock price. MRUS (Merus N.V.)")
The difference between the consensus estimate and the actual stock price MRUS (Merus N.V.)
Merus N.V. is a biotech company specializing in the development of bispecific antibodies for cancer treatment. Their technology allows a single drug to attack two cancer targets simultaneously. This chart reflects analyst expectations for their clinical pipeline, particularly in lung and ovarian cancer. It shows the gap between the target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MRUS-Merus-N.V.&v=1772545611634 "A chart showing the difference between the consensus forecast and the actual stock price. MRUS (Merus N.V.)")
Analyst consensus forecast for stock prices by market segment - Cancer women
Merus is a Dutch biotech company using its "Biclonics" platform to create bispecific antibodies that can attack cancer cells through two distinct pathways. This chart shows analysts' overall expectations across the oncology sector, reflecting whether experts believe this complex R&D platform will be successful.
Analysts' consensus forecast for the overall market share price
Merus N.V. (MRUS) is a biotech company specializing in bispecific antibodies (cancer treatment). This is an R&D project. (Note: the "Cancer Women" category is inaccurate; they cover a broad range of oncology.) This chart, reflecting expert expectations, is a measure of risk appetite. During a downturn (pessimism), investors flee cash-burning biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Merus N.V.
Merus is a clinical-stage biotech company developing bispecific antibodies for cancer treatment. Their technology enables a single molecule to attack two tumor targets simultaneously. This chart is a clear indicator of biotech expectations. It aggregates their clinical trial data, the assessment of their Biclonics R&D platform, and market confidence in their scientific approach.
AKIMA Market Segment Index - Cancer women
Merus is a Dutch R&D biotech (oncology) that has developed the unique Multiclonics platform for creating bispecific antibodies (attacking cancer from both sides). This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does Merus's innovative R&D platform (bispecifics) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Merus is a Dutch biotech company focused on developing bispecific antibodies for cancer treatment. It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, compares to overall economic trends.
